Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca Raffaelli

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Frontiers in Neurology|October 13, 2023
Editorial: Spotlight on resistant and refractory migraineRaffaele Ornello, Bianca Raffaelli
Fortschritte Der Neurologie-Psychiatrie|March 28, 2024
[Anti-CGRP-based Migraine Medications: A Comprehensive Overview]Paul Triller, Bianca Raffaelli
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 5, 2018
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine TherapyBianca Raffaelli, Uwe Reuter
Expert Opinion on Drug Safety|December 6, 2025
Safety and tolerability of fremanezumab for treating migraine: where are we now?Carolin Luisa Hoehne, Bianca Raffaelli
Der Nervenarzt|February 6, 2024
[Migraine and pregnancy : Gender-specific aspects and current knowledge]Bianca Raffaelli, Kristin S Lange
Expert Opinion on Pharmacotherapy|June 14, 2022
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraineMira Fitzek, Bianca Raffaelli, Uwe Reuter
Cephalalgia : an International Journal of Headache|January 23, 2026
2025 Highlights in acute migraine treatmentBianca Raffaelli, Marcio Nattan Portes Souza
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
Schmerz (Berlin, Germany)|April 17, 2026
[Migraine in men: biological, psychosocial and clinical characteristics]Carolin Luisa Hoehne, Wiebke Andersen, Bianca Raffaelli
Expert Opinion on Pharmacotherapy|July 28, 2017
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraineBianca Raffaelli, Heike Israel, Lars Neeb, et al.
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Frontiers in Neurology|October 13, 2023
Editorial: Spotlight on resistant and refractory migraineRaffaele Ornello, Bianca Raffaelli
Fortschritte Der Neurologie-Psychiatrie|March 28, 2024
[Anti-CGRP-based Migraine Medications: A Comprehensive Overview]Paul Triller, Bianca Raffaelli
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 5, 2018
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine TherapyBianca Raffaelli, Uwe Reuter
Expert Opinion on Drug Safety|December 6, 2025
Safety and tolerability of fremanezumab for treating migraine: where are we now?Carolin Luisa Hoehne, Bianca Raffaelli
Der Nervenarzt|February 6, 2024
[Migraine and pregnancy : Gender-specific aspects and current knowledge]Bianca Raffaelli, Kristin S Lange
Expert Opinion on Pharmacotherapy|June 14, 2022
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraineMira Fitzek, Bianca Raffaelli, Uwe Reuter
Cephalalgia : an International Journal of Headache|January 23, 2026
2025 Highlights in acute migraine treatmentBianca Raffaelli, Marcio Nattan Portes Souza
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
Schmerz (Berlin, Germany)|April 17, 2026
[Migraine in men: biological, psychosocial and clinical characteristics]Carolin Luisa Hoehne, Wiebke Andersen, Bianca Raffaelli
Expert Opinion on Pharmacotherapy|July 28, 2017
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraineBianca Raffaelli, Heike Israel, Lars Neeb, et al.
Pageof 10